Rigetti Computing, Inc. Common Stock
RGTI
$15.09
-1.18%
Rigetti Computing, Inc. designs and builds superconducting quantum computers and the quantum processors that power them, selling 9-qubit to 108-qubit systems under the Novera and Cepheus brands and delivering access through its Rigetti Quantum Cloud Services (QCS) platform, which can be integrated into public, private, or hybrid clouds. The company operates in the Technology sector within the Computer Hardware industry, positioning itself as a vertically integrated pure-play quantum hardware and cloud-access provider rather than a diversified IT vendor, with operations spanning Fremont, London, Adelaide, British Columbia, and Mumbai and a lean headcount of roughly 164 employees. The current investor narrative is dominated by the tension between strategic validation and commercial immaturity: a $100 million CHIPS Act award announced in early September 2026 has been widely framed as government endorsement of Rigetti's technology roadmap, yet the company remains pre-commercial with negligible revenue and no near-term path to profitability. At the same time, media coverage has highlighted a broader quantum-sector cash test into 2028 and roughly $857 million of insider selling across leading quantum names over two years with virtually no insider buying, leaving the stock caught between speculative enthusiasm for a federal funding cycle and growing scrutiny of cash runway, dilution risk, and valuation disconnected from current fundamentals.…
RGTI
Rigetti Computing, Inc. Common Stock
$15.09
Related headlines
Investment Opinion: Should I buy RGTI Today?
Rating: Hold. Rigetti offers a speculative option on quantum computing's future, validated by a $100M CHIPS Act award and a Buy consensus from 12 analysts with an average target of $28.81 (88.7% upside). However, the company is pre-commercial with negative gross margins and a 968x PS ratio, making it unsuitable for most investors. The risk/reward is skewed by extreme valuation and cash burn, but the government backing and analyst support prevent a Sell rating.
Supporting evidence includes: (1) Q1 2026 revenue growth of 198.9% YoY to $4.4M, albeit from a tiny base; (2) a fortress balance sheet with current ratio of 37.4 and debt-to-equity of 0.013; (3) negative free cash flow of -$81.6M TTM, highlighting the need for external funding; (4) analyst average target of $28.81, implying significant upside if milestones are met; and (5) a PEG ratio of 0.88, suggesting growth-adjusted value if forward estimates are achievable. The 968x PS ratio and -30.5% net margin underscore the disconnect between price and current fundamentals.
The biggest risks are dilution (shares up 79.8% since Q4 2024), competitive pressure from IonQ and D-Wave, and the 2028 cash test that could force a capital raise. The rating would upgrade to Buy if revenue exceeds $20M annually with improving gross margins, or downgrade to Sell if cash burn accelerates or government funding fails to translate into commercial contracts. Relative to peers and its own history, RGTI is overvalued on current metrics but may be fairly valued if it captures a meaningful share of the quantum market by 2030.
Sign up to view all
RGTI 12-Month Price Forecast
Rigetti presents a high-risk, high-reward opportunity that is currently in a show-me phase. The $100M CHIPS Act award and analyst Buy consensus provide a floor, but the 968x PS ratio and negative margins leave little room for error. The base case (50% probability) assumes steady progress toward $221M revenue and a stock price around $28.81, but this requires flawless execution. A downgrade to bearish would occur if cash burn accelerates or government funding fails to yield commercial contracts; an upgrade to bullish would require revenue exceeding $20M annually with improving gross margins and no dilutive financing.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Rigetti Computing, Inc. Common Stock's 12-month outlook, with a consensus price target around $28.81 and implied upside of +90.9% versus the current price.
Average Target
$28.81
0 analysts
Implied Upside
+90.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $40
Analyst target range
Bulls vs Bears: RGTI Investment Factors
The bear case currently has stronger evidence: Rigetti is pre-commercial with negative gross margins, a 968x PS ratio, and $81.6M in annual cash burn, while insiders have sold $857M with no buying. The bull case rests almost entirely on the $100M CHIPS Act award and analyst targets that assume flawless execution toward a commercial quantum future that may be years away. The single most important tension is whether government funding and strategic partnerships can bridge the company to commercial viability before cash reserves force dilutive financing. If Rigetti can demonstrate recurring revenue growth above $20M annually without massive dilution, the bull case gains credibility; otherwise, the stock risks a sharp re-rating toward its 52-week low of $12.53.
Bullish
- CHIPS Act Award Validates Technology: The $100 million CHIPS Act award announced in early September 2026 provides government endorsement of Rigetti's superconducting quantum roadmap. This non-dilutive funding extends cash runway and signals strategic importance to U.S. quantum leadership.
- Analyst Consensus Buy with 89% Upside: 12 analysts rate RGTI a Buy (recommendation mean 1.69) with an average target price of $28.81, implying 88.7% upside from the current $15.27. The high target of $40.00 suggests significant optionality if milestones are met.
- Fortress Balance Sheet with 37x Current Ratio: Current ratio of 37.4 and debt-to-equity of just 0.013 indicate negligible near-term solvency risk. Interest income of $5.36M in Q1 2026 further offsets operating cash burn.
- Revenue Growth Inflection in Q1 2026: Q1 2026 revenue of $4.4M grew 198.9% year-over-year, the strongest growth rate in recent quarters. This suggests early commercial traction for Novera and Cepheus systems.
Bearish
- Extreme Valuation Disconnected from Fundamentals: Price-to-sales of 968x and EV-to-sales of 350x are among the highest in the market, with a market cap of $6.86B against TTM revenue of roughly $7M. The stock prices in decades of future growth that may never materialize.
- Pre-Commercial with Negative Gross Margins: Gross margin is -0.86% and operating margin is -11.94%, meaning Rigetti loses money on every dollar of revenue. Net margin of -30.5% and negative free cash flow of -$81.6M TTM highlight the cash burn.
- Insider Selling of $857M with No Buying: Across leading quantum names, insiders have sold $857 million over two years with virtually no open-market purchases. This divergence between insider behavior and bullish analyst ratings is a major red flag.
- Severe Underperformance and High Beta: RGTI is down 35.3% YTD and 27.2% over three months, massively underperforming SPY's +12.1% YTD and +3.0% 3-month returns. Beta of 2.01 amplifies downside during market stress.
RGTI Technical Analysis
Beta
2.01
2.01x market volatility
Max Drawdown
-77.1%
Largest decline past year
52-Week Range
$13-$58
Price range past year
Annual Return
-21.4%
Cumulative gain past year
| Period | RGTI Return | S&P 500 |
|---|---|---|
| 1m | -19.8% | -2.4% |
| 3m | -25.5% | +2.2% |
| 6m | -2.1% | +14.8% |
| 1y | -21.4% | +14.6% |
| ytd | -36.1% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RGTI Fundamental Analysis
Quarterly Revenue
$4400000.0B
2026-03
Revenue YoY Growth
+198.9%
YoY Comparison
Gross Margin
-28.1%
Latest Quarter
Free Cash Flow
$-81648000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RGTI Overvalued?
PE
-31.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.8x
Enterprise Value Multiple
Investment Risk Disclosure
Rigetti's financial risks are acute: negative gross margin of -0.86% means the company loses money on product sales, while operating margin of -11.94% and net margin of -30.5% reflect heavy R&D spending ($19.96M in Q1 2026 alone). Free cash flow is -$81.6M TTM, and although the current ratio of 37.4 and debt-to-equity of 0.013 provide a cushion, the company has no debt but also no revenue scale. Revenue concentration is extreme, with total TTM revenue around $7M and Q1 2026 revenue of $4.4M representing a single quarter's spike; sustainability is unproven. The 79.8% increase in shares outstanding from Q4 2024 to Q1 2026 signals that equity dilution is already a material risk.
Market and competitive risks are amplified by RGTI's beta of 2.01, meaning it moves twice as fast as the broader market in both directions. The stock trades at a 968x PS ratio and 12.6x book, leaving no margin for error; any disappointment in quantum milestones or government funding could trigger a severe valuation compression. Competition from IonQ, D-Wave, and GlobalFoundries—which received a larger government award—threatens Rigetti's differentiation. Regulatory headwinds are minimal, but the sector faces a "2028 cash test" that could force consolidation or failures, and insider selling of $857M across quantum names suggests smart money is de-risking.
In a worst-case scenario, Rigetti fails to secure follow-on government funding or commercial contracts, forcing a dilutive equity raise at depressed prices. The stock could retrace to its 52-week low of $12.53, representing a 17.9% decline from the current $15.27, or worse if the 2028 cash test triggers a sector-wide selloff. Given the max drawdown of -77.1%, a more severe scenario could see RGTI fall below $10, implying a 34%+ loss. The analyst low target of $18.00 is above the current price, but that assumes no deterioration; a funding failure could easily push the stock to single digits.
FAQ
The most severe risk is dilution: shares outstanding increased 79.8% from Q4 2024 to Q1 2026, and with negative free cash flow of $81.6M TTM, another capital raise is likely. Second, competitive risk from IonQ and D-Wave, which are better capitalized and have larger government awards, could erode Rigetti's market position. Third, valuation risk: a 968x PS ratio means any disappointment could trigger a sharp selloff, as seen in the 77.1% max drawdown. Finally, macro risk: beta of 2.01 makes the stock highly sensitive to market downturns and sector rotation away from speculative tech.
Our 12-month forecast has three scenarios: Bull (25% probability) targeting $40-$58.15 if commercial contracts and technical milestones are achieved; Base (50% probability) targeting $18-$28.81, assuming steady progress and analyst average revenue of $221M; and Bear (25% probability) targeting $12.53-$18.00 if funding fails or dilution accelerates. The base case is most likely, hinging on Rigetti converting its CHIPS Act award into commercial traction without massive dilution. Analyst average target of $28.81 aligns with the base case.
RGTI is significantly overvalued on current fundamentals, with a price-to-sales ratio of 968x and EV-to-sales of 350x, compared to typical hardware peers trading at 1-5x sales. The market is pricing in decades of future growth, assuming Rigetti captures a large share of the quantum computing market. However, the PEG ratio of 0.88 suggests that if forward earnings estimates are met, the stock could be reasonably valued on a growth-adjusted basis. The disconnect between current revenue of ~$7M TTM and a $6.86B market cap highlights the speculative premium.
RGTI is a high-risk, speculative buy only for investors who can tolerate extreme volatility and potential loss of capital. The analyst consensus is Buy with an average target of $28.81, implying 88.7% upside, but the stock trades at 968x sales with negative gross margins and $81.6M in annual cash burn. The $100M CHIPS Act award provides validation, but commercial adoption remains unproven. For most investors, a Hold rating is more appropriate until revenue scales and margins improve.
RGTI is suitable only for long-term, risk-tolerant investors with a minimum 5-year horizon, as the quantum computing market may not mature until the 2030s. The stock's beta of 2.01 and 77.1% max drawdown make it unsuitable for short-term trading unless one is a speculator. No dividend is paid, so returns depend entirely on capital appreciation. Earnings visibility is low, with negative EPS and no clear path to profitability, so investors should be prepared for volatility and potential dilution. A small position size (e.g., 1-2% of portfolio) is prudent.